PMID- 28144882
OWN - NLM
STAT- MEDLINE
DCOM- 20170919
LR  - 20181202
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 22
IP  - 3
DP  - 2017 Jun
TI  - Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin 
      and gelatin sponge in patients with liver metastases from uveal melanoma in an 
      Asian population.
PG  - 577-584
LID - 10.1007/s10147-017-1095-0 [doi]
AB  - BACKGROUND: Although both immune-checkpoint inhibitors and targeted therapies 
      such as MEK inhibitors have been evaluated in metastatic uveal melanoma, the 
      efficacy of these therapies is modest to date. The purpose of this study was to 
      evaluate the efficacy and toxicity of transarterial chemoembolization (TACE) 
      therapy for liver metastasis from uveal melanoma in an Asian population. METHODS: 
      We retrospectively assessed the clinical data of patients with liver metastases 
      from uveal melanoma who received TACE therapy using cisplatin (70 mg/m(2)) and 
      gelatin sponge between 1997 and 2008. RESULTS: We identified 29 eligible 
      patients. The overall response rate was 21%. The median survival time was 
      23 months, and the 1-, 2-, and 5-year survival rates were 72.4, 39.4, and 0%, 
      respectively. The favorable prognostic factors were partial response and stable 
      disease, <25% of the tumor volume within the liver at baseline, and normal serum 
      lactate dehydrogenase (LDH) and normal alkaline phosphatase at baseline. Among 
      them, normal LDH at baseline was the only independent prognostic factor in 
      multivariate analysis. The common adverse events (AEs) were liver enzyme 
      elevation (100%), nausea (72.4%), abdominal pain (65.5%), vomiting (55.2%), 
      post-embolization syndrome (34.5% of patients, 9.6% of TACE procedures), and 
      pyrexia (24.1%). Grade >/=3 AEs consisted of aspartate aminotransferase elevation 
      (34.5%), alanine aminotransferase elevation (51.7%), and serum creatinine 
      elevation (3.4%). CONCLUSION: TACE therapy has a certain degree of clinical 
      efficacy with a tolerable toxicity and, therefore, can still be one of the 
      treatment options. However, considering the lack of long-term efficacy of this 
      therapy, further treatment strategies need to be developed.
FAU - Shibayama, Yoshitsugu
AU  - Shibayama Y
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
AD  - Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Jonan-ku, Fukuoka, 814-0133, Japan.
FAU - Namikawa, Kenjiro
AU  - Namikawa K
AUID- ORCID: 0000-0003-2763-7346
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. knamikaw@ncc.go.jp.
FAU - Sone, Miyuki
AU  - Sone M
AD  - Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Takahashi, Akira
AU  - Takahashi A
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Tsutsumida, Arata
AU  - Tsutsumida A
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Sugawara, Shunsuke
AU  - Sugawara S
AD  - Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Arai, Yasuaki
AU  - Arai Y
AD  - Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Aihara, Yukiko
AU  - Aihara Y
AD  - Department of Ophthalmic Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Suzuki, Shigenobu
AU  - Suzuki S
AD  - Department of Ophthalmic Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Nakayama, Juichiro
AU  - Nakayama J
AD  - Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Jonan-ku, Fukuoka, 814-0133, Japan.
FAU - Imafuku, Shinichi
AU  - Imafuku S
AD  - Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 
      Nanakuma, Jonan-ku, Fukuoka, 814-0133, Japan.
FAU - Yamazaki, Naoya
AU  - Yamazaki N
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170131
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Antineoplastic Agents)
RN  - 9000-70-8 (Gelatin)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Uveal melanoma
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - Cisplatin/therapeutic use
MH  - Female
MH  - Gelatin
MH  - Humans
MH  - Liver Neoplasms/mortality/*secondary/*therapy
MH  - Male
MH  - Melanoma/mortality/*pathology
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Tumor Burden
MH  - Uveal Neoplasms/mortality/*pathology
OTO - NOTNLM
OT  - Asian
OT  - Cisplatin
OT  - Liver metastasis
OT  - Melanoma
OT  - TACE
OT  - Uveal
EDAT- 2017/02/02 06:00
MHDA- 2017/09/20 06:00
CRDT- 2017/02/02 06:00
PHST- 2016/09/22 00:00 [received]
PHST- 2017/01/20 00:00 [accepted]
PHST- 2017/02/02 06:00 [pubmed]
PHST- 2017/09/20 06:00 [medline]
PHST- 2017/02/02 06:00 [entrez]
AID - 10.1007/s10147-017-1095-0 [pii]
AID - 10.1007/s10147-017-1095-0 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2017 Jun;22(3):577-584. doi: 10.1007/s10147-017-1095-0. Epub 
      2017 Jan 31.